Trends in Psychiatry and Psychotherapy
https://trends.org.br/article/doi/10.1590/2237-6089-2016-0053
Trends in Psychiatry and Psychotherapy
Original Article

Trends in the prescription of clozapine in a psychiatric hospital: a 5-year observational study

Tendência na prescrição de clozapina em um hospital psiquiátrico: estudo observacional de 5 anos

Gabriela Danielski Niehues; Alexandre Balestieri Balan; Vinicius Brum Prá; Raphaela Santos Pellizzaro; Paulo Roberto Antunes da Silva; Manuela Danielski Niehues; Ana Paula Costa; Marcelo Liborio Schwarzbold; Alexandre Paim Diaz

http://dx.doi.org/10.1590/2237-6089-2016-0053 Trends Psychiatry Psychother, vol.39, n3, p.158-164, 2017
PDF
SciELO
Downloads: 0
Views: 579

Abstract

Abstract Introduction Clozapine is a well-recognized effective treatment for some patients with treatment-resistant schizophrenia (TRS). Although it has potential benefits and approximately 30% of patients have a clinical indication for clozapine use, prescription rates are low. Objective To evaluate clozapine prescription trends over a 5-year period in a tertiary psychiatric hospital. Methods In this observational study, data prospectively collected by the Medical and Statistical File Service (Serviço de Arquivo Médico e Estatístico) and the Pharmacy Division of Instituto de Psiquiatria de Santa Catarina between January 2010 and December 2014 were summarized and analyzed by investigators blinded to data collection. The number of 100 mg clozapine pills dispensed by the Pharmacy Division to the inpatient units was the outcome and considered a proxy measure of clozapine prescriptions. The number of occupied inpatient unit beds and the number of patients admitted with F20-F29 (ICD-10) diagnoses during the study period were considered to be possible confounders. Results A multiple linear regression model showed that time in months was independently associated with an increase in the number of clozapine pills dispensed by the Pharmacy Division (β coefficient = 15.82; 95% confidence interval 10.88-20.75). Conclusion Clozapine prescriptions were found to have increased during the 5-year period studied, a trend that is opposite to reports from several other countries.

Keywords

Clozapine, inpatient psychiatry, pharmacoepidemiology

Resumo

Resumo Introdução Clozapina é um medicamento reconhecidamente eficaz para alguns pacientes com esquizofrenia refratária ao tratamento. Apesar dos seus potenciais benefícios e de sua indicação clínica para aproximadamente 30% dos pacientes, a frequência de prescrição de clozapina é baixa. Objetivos Avaliar a tendência na prescrição de clozapina durante um período de 5 anos em um hospital psiquiátrico. Métodos Neste estudo observacional, dados coletados prospectivamente pelo Serviço de Arquivo Médico e Estatístico e pela Divisão de Farmácia (DF) do Instituto de Psiquiatria de Santa Catarina foram analisados por pesquisadores cegos para a coleta de dados. O número de comprimidos de clozapina 100 mg dispensados pela DF às enfermarias foi considerado a variável dependente e a medida de prescrição de clozapina. Número de leitos de internação ocupados e número de pacientes admitidos com diagnósticos F20-F29 (CID-10) durante o período de estudo foram considerados possíveis confundidores. Resultados Após análise com modelo de regressão linear múltipla, tempo em meses foi independentemente associado com aumento do número de comprimidos de clozapina 100 mg dispensados pela DF (coeficiente β = 15,82; intervalo de confiança de 95% 10,88-20,75). Conclusão Houve um aumento na prescrição de clozapina durante o período de 5 anos estudado, uma tendência oposta à relatada em vários outros países.

Palavras-chave

Clozapina, farmacoepidemiologia, internação psiquiátrica

References

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-10.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-62.

Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173:166-73.

Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65:186-92.

Olfson M, Gerhard T, Crystal S, Stroup TS. Clozapine for schizophrenia: state variation in evidence-based practice. Psychiatr Serv. 2016;67.

Tungaraza TE, Farooq S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol. 2015;5:88-96.

Grover S, Balachander S, Chakarabarti S, Avasthi A. Prescription practices and attitude of psychiatrists towards clozapine: A survey of psychiatrists from India. Asian J Psychiatr. 2015;18:57-65.

Kelly DL, Wehring HJ, Vyas G. Current status of clozapine in the United States. Shanghai Arch Psychiatry. 2012;24:110-3.

Klebovich A, Reszegi CA, Zelko R. Utilization study of clozapine, olanzapine and risperidone in Hungary. Acta Pharm Hung. 2004;74:233-6.

Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14.

Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992;63:51-70.

De Berardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf. 2012;7:55-62.

Bogorni F, Moreira FF, Pimentel EM, Grohs GE, Diaz AP. Amisulpride augmentation for clozapine-refractory positive symptoms: additional benefit in reducing hypersialorrhea. Case Rep Psychiatry. 2015;2015.

Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013;33:713-4.

Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand. 2014;130:16-24.

Werneck AP, Hallak JC, Nakano E, Elkis H. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res. 2011;188:315-9.

The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. 1993.

Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry. 2012;27:129-41.

Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15:1351-71.

Raja M, Raja S. Clozapine safety, 40 years later. Curr Drug Saf. 2014;9:163-95.

Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry. 2015;48:11-4.

Winckel K, Siskind D, Hollingworth S, Robinson G, Mitchell S, Varghese D. Clozapine in the community: Improved access or risky free-for-all?. Aust N Z J Psychiatry. 2015;49:863-5.

Malalagama G, Bastiampillai T, Dhillon R. Clozapine prescription patterns in Australia over the last 10 years. Aust N Z J Psychiatry. 2011;45:498-9.

Carruthers J, Radigan M, Erlich MD, Gu G, Wang R, Frimpong EY. An initiative to improve clozapine prescribing in New York State. Psychiatr Serv. 2016;67:369-71.

6169d28ba953955659195be2 trends Articles
Links & Downloads
2238-0019 (Electronic)
Trends Psychiatry Psychother ©2024 All rights reserved.

Trends Psychiatry Psychother

Share this page
Page Sections